ASCO: Amgen's KRAS drug shows 'modest' efficacy beyond NSCLC
ASCO: Amgen's KRAS drug shows 'modest' efficacy beyond NSCLC ntaylor Thu, 05/14/2020 - 08:11

Jul 28, 2020 0 46
Mar 24, 2020 0 33
Apr 10, 2020 0 23
Apr 27, 2020 0 22
Apr 10, 2020 0 19
Mar 13, 2020 0 271
Mar 26, 2020 0 111
AstraZeneca is set to pay Silence Therapeutics $60 million (€55 million) to work...
Mar 17, 2020 0 121
Sierra Oncology deprioritized the development of its CHK1 blocker SRA737 last year,...
Apr 23, 2020 0 103
Credit: NOAA Not long ago, the azure waters of the Caribbean contained healthy and...
May 4, 2020 0 102
Credit: Center for Marine Environmental Sciences (MARUM), University of Bremen WOODS...
May 19, 2020 0 83
Credit: Daniel Haskel It sounds like a riddle: What do you get if you take two small...
May 22, 2020 0 98
Less severe fire locks away huge amounts of carbon and keeps it from entering the...